ACM
KYMR icon

Aquilo Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Aquilo Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-138,521
Closed -$3.79M – 9
2025
Q1 		$3.79M Sell
138,521
-45,000
-25% -$1.64M 6.8% 5
2024
Q4 		$7.38M Sell
183,521
-25,222
-12% -$1.14M 11.13% 3
2024
Q3 		$9.88M Sell
208,743
-120,000
-37% -$5.3M 7.49% 4
2024
Q2 		$9.81M Sell
328,743
-60,000
-15% -$2.08M 9.46% 5
2024
Q1 		$15.6M Sell
388,743
-492,594
-56% -$17.6M 11.71% 5
2023
Q4 		$22.4M Buy
881,337
+99,118
+13% +$1.77M 13.98% 3
2023
Q3 		$10.9M Buy
782,219
+130,894
+20% +$2.63M 9.85% 5
2023
Q2 		$15M Buy
651,325
+50,000
+8% +$1.43M 8.3% 7
2023
Q1 		$17.8M Sell
601,325
-28,086
-4% -$906K 7.38% 5
2022
Q4 		$15.7M Buy
629,411
+299,165
+91% +$7.98M 5.9% 8
2022
Q3 		$7.19M Buy
+330,246
New +$8.7M 2.59% 12

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Aquilo Capital Management's KYMR Position: Q2 2025 in Review

Aquilo Capital Management sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 138,521 shares — an estimated $3.79M sold.

Aquilo Capital Management first reported a position in KYMR in Q3 2022 and held it in 11 quarters. The position peaked at $22.4M in Q4 2023. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • Aquilo Capital Management reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Aquilo Capital Management sold 138,521 Kymera Therapeutics shares in Q2 2025, an estimated $3.79M.
  • Aquilo Capital Management first reported a position in Kymera Therapeutics in Q3 2022 and held it in 11 quarters.
  • Aquilo Capital Management's Kymera Therapeutics position peaked at $22.4M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on Aquilo Capital Management's 13F filing for Q2 2025.